Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 164-169

  Ma, Hongxia ^a   Shu, Yongqian ^a,b   Pan, Shiyang ^b   Chen, Jiaping ^a,c   Dai, Juncheng ^a   Jin, Guangfu ^a   Hu, Zhibin ^a,c   Shen, Hongbing ^a,b,c  

^a Nanjing Medical University   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; CCL8; Chemokine; NSCLC; Polymorphism; Survival

Indexed keywords

CHEMOKINE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CCL2 GENE; CCL20 GENE; CCL22 GENE; CCL5 GENE; CCL8 GENE; CHINESE; CXCL1 GENE; CXCL12 GENE; CXCL6 GENE; CXCL9 GENE; DNA FLANKING REGION; DNA POLYMORPHISM; GENE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINES; CHINA; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS;

EID: 80053652279     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.03.005     Document Type: Article

References (45)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350(4):351-360.
3. Locati M., Otero K., Schioppa T., Signorelli P., Perrier P., Baviera S., et al. The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy 2002, 57(11):972-982.
4. Singh S., Sadanandam A., Singh R.K. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007, 26(3-4):453-467.
5. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12(2):121-127.
6. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256(2):137-165.
7. Gerber P.A., Hippe A., Buhren B.A., Müller A., Homey B. Chemokines in tumor-associated angiogenesis. Biol Chem 2009, 390(12):1213-1223.
8. Beider K., Abraham M., Begin M., Wald H., Weiss I.D., Wald O., et al. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One 2009, 4(4):e5125.
9. Addison C.L., Arenberg D.A., Morris S.B., Xue Y.Y., Burdick M.D., Mulligan M.S., et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000, 11(2):247-261.
10. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267(2):271-285.
11. Aggarwal B.B., Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr Opin Pharmacol 2009, 9(4):351-369.
12. Suzuki M., Mohamed S., Nakajima T., Kubo R., Tian L., Fujiwara T., et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 2008, 33(1):113-119.
13. Yuan A., Yang P.C., Yu C.J., Chen W.J., Lin F.Y., Kuo S.H., et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000, 162(5):1957-1963.
14. Nakanishi T., Imaizumi K., Hasegawa Y., Kawabe T., Hashimoto N., Okamoto M., et al. Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. Cancer Immunol Immunother 2006, 55(11):1320-1329.
15. Ghilardi G., Biondi M.L., La Torre A., Battaglioli L., Scorza R. Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem 2005, 51(2):452-455.
16. Tse K.P., Tsang N.M., Chen K.D., Li H.P., Liang Y., Hsueh C., et al. MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res 2007, 13(21):6320-6326.
17. Razmkhah M., Talei A.R., Doroudchi M., Khalili-Azad T., Ghaderi A. Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett 2005, 225(2):261-266.
18. Razmkhah M., Doroudchi M., Ghayumi S.M., Erfani N., Ghaderi A. Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer 2005, 49(3):311-315.
19. Hirata H., Hinoda Y., Kikuno N., Kawamoto K., Dahiya A.V., Suehiro Y., et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 2007, 13(17):5056-5062.
20. Hidalgo-Pascual M., Galan J.J., Chaves-Conde M., Ramírez-Armengol J.A., Moreno C., Calvo E., et al. Analysis of CXCL12 3'UTR G>A polymorphism in colorectal cancer. Oncol Rep 2007, 18(6):1583-1587.
21. Vairaktaris E., Vylliotis A., Spyridonodou S., Derka S., Vassiliou S., Nkenke E., et al. A DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. Anticancer Res 2008, 28(1A):271-275.
22. Chang C.C., Chen S.C., Hsieh Y.H., Chen Y.C., Chen T.Y., Chu Y.H., et al. Stromal cell-derived factor-1 but not its receptor CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med 2009, 47(4):412-418.
23. Nahon P., Sutton A., Rufat P., Simon C., Trinchet J.C., Gattegno L., et al. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 2008, 14(5):713-719.
24. Chang S.C., Lin P.C., Yang S.H., Wang H.S., Li A.F., Lin J.K. SDF-1alpha G801A polymorphism predicts lymph node metastasis in stage T3 colorectal cancer. Ann Surg Oncol 2009, 16(8):2323-2330.
25. Coelho A., Calçada C., Catarino R., Pinto D., Fonseca G., Medeiros R. CXCL12-3' A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?. Cancer Immunol Immunother 2006, 55(6):639-643.
26. Dommange F., Cartron G., Espanel C., Gallay N., Domenech J., Benboubker L., et al. CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J 2006, 20(11):1913-1915.
27. Nahon P., Sutton A., Rufat P., Faisant C., Simon C., Barget N., et al. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol 2007, 19(5):425-431.
28. Zhang M., Hu Z., Huang J., Shu Y., Dai J., Jin G., et al. A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010, 16(4):1236-1244.
29. Greene F.L. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002, 87(July (7)):13-15.
30. Hu Z., Wang H., Shao M., Jin G., Sun W., Wang Y., et al. Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. Hum Mutat 2007, 28(5):431-440.
31. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006, 25(3):357-371.
32. Strieter R.M., Burdick M.D., Mestas J., Gomperts B., Keane M.P., Belperio J.A., et al. Cancer 2006, 42(6):768-778.
33. Zhang J., Patel L., Pienta K.J. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010, 21(1):41-48.
34. Conti I., Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004, 14(3):149-154.
35. Negus R.P., Stamp G.W., Relf M.G., Burke F., Malik S.T., Bernasconi S., et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995, 95(5):2391-2396.
36. Arenberg D.A., Keane M.P., DiGiovine B., Kunkel S.L., Strom S.R., Burdick M.D., et al. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother 2000, 49(2):63-70.
37. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000, 6(8):3282-3289.
38. Van Damme J., Proost P., Lenaerts J.P., Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992, 176(1):59-65.
39. Kastenbauer S., Angele B., Sporer B., Pfister H.W., Koedel U. Patterns of protein expression in infectious meningitis: a cerebrospinal fluid protein array analysis. J Neuroimmunol 2005, 164(1-2):134-139.
40. Bièche I., Asselah T., Laurendeau I., Vidaud D., Degot C., Paradis V., et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005, 332(1):130-144.
41. Hellier S., Frodsham A.J., Hennig B.J., Klenerman P., Knapp S., Ramaley P., et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003, 38(6):1468-1476.
42. Tsuneyama K., Harada K., Yasoshima M., Hiramatsu K., Mackay C.R., Mackay I.R., et al. Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: implications for pathogenesis. J Pathol 2001, 193(1):102-109.
43. Vande Broek I., Asosingh K., Vanderkerken K., Straetmans N., Van Camp B., Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003, 88(6):855-862.
44. Struyf S., Proost P., Vandercappellen J., Dempe S., Noyens B., Nelissen S., et al. Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur J Immunol 2009, 39(3):843-857.
45. Bidwell J., Keen L., Gallagher G., Kimberly R., Huizinga T., McDermott M.F., et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2001, 2(2):61-70.